Article

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials-08-01-2003
Volume

Bayesian, Likelihood, and Frequentist Approaches to Statistics

Bayesian isn?t the most popular statistical method yet, but it is gaining ground in a number of clinical trials areas.

External Link - article-64955.pdf

Articles in this issue
My Fiefdom, Right or Wrong
Information Showcase
What?s Old Is New Again
Strategy and Tactics for European Clinical Trials
21 CFR 11 Compliance for Clinical Data
Bayesian, Likelihood, and Frequentist Approaches to Statistics

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
Is FDA Trial Design Scrutiny Increasing or Just Less Predictable?
Is FDA Trial Design Scrutiny Increasing or Just Less Predictable?
What the Future Holds for Clinical Trials as AI and Digital Twins Become More Embedded
What the Future Holds for Clinical Trials as AI and Digital Twins Become More Embedded
Enhancing Clinical Trial Integrity Through AI and Digital Twin Technologies
Enhancing Clinical Trial Integrity Through AI and Digital Twin Technologies
Related Content
© Destina - © Destina - stock.adobe.com
August 15th 2025

Phase II B-SUPREME Trial Launches for ALG-000184 in Chronic Hepatitis B

Andy Studna, Senior Editor
ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials
August 15th 2025

ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials

Andy Studna, Senior Editor
Q&A: How AI Is Reshaping Clinical Operations and Study Feasibility
August 15th 2025

Q&A: How AI Is Reshaping Clinical Operations and Study Feasibility

Andy Studna, Senior Editor
ACT Brief Episode 2: FDA Oversight, Vaccine Funding Cuts, and the Digital Future of Clinical Trials
August 15th 2025

ACT Brief Episode 2: FDA Oversight, Vaccine Funding Cuts, and the Digital Future of Clinical Trials

Andy Studna, Senior Editor
Jim DiCesare, Vice President, Financial Management Solutions, IQVIA Technologies
August 15th 2025

Why Sponsors Should Consider a Hybrid Approach for Clinical Trial Payments

Jim DiCesare
© AkuAku - © AkuAku - stock.adobe.com
August 15th 2025

Phase III VAYHIT2 Trial Demonstrates Ianalumab Plus Eltrombopag Extends Disease Control in Primary Immune Thrombocytopenia

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.